Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Enterprise Value (2017 - 2025)

Protagonist Therapeutics' Enterprise Value history spans 9 years, with the latest figure at -$567.4 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 35.44% year-over-year to -$567.4 million; the TTM value through Dec 2025 reached -$567.4 million, down 35.44%, while the annual FY2025 figure was -$567.4 million, 35.44% down from the prior year.
  • Enterprise Value for Q4 2025 was -$567.4 million at Protagonist Therapeutics, up from -$576.1 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$120.5 million in Q2 2022 and bottomed at -$576.1 million in Q3 2025.
  • The 5-year median for Enterprise Value is -$321.7 million (2023), against an average of -$365.3 million.
  • The largest annual shift saw Enterprise Value tumbled 354.09% in 2021 before it soared 37.47% in 2022.
  • A 5-year view of Enterprise Value shows it stood at -$326.9 million in 2021, then rose by 27.38% to -$237.4 million in 2022, then crashed by 43.93% to -$341.6 million in 2023, then dropped by 22.62% to -$418.9 million in 2024, then tumbled by 35.44% to -$567.4 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Enterprise Value are -$567.4 million (Q4 2025), -$576.1 million (Q3 2025), and -$570.5 million (Q2 2025).